HAYWARD, Calif.--(BUSINESS WIRE)--Apr. 30, 2018--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced that the Company
will report first quarter 2018 financial results and operational
highlights on Tuesday, May 8, 2018. Pulse Biosciences management will
host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30
p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing
(844) 494-0190 (domestic) and (508) 637-5580 (international) using the
conference ID# 4796365. The webcast of the conference call can be
accessed live on the Investor Relations section of the Pulse Biosciences
website at www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a clinical stage electroceutical, an electrical
energy based therapeutic, company pursuing commercial applications of
its proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a
non-thermal, precise, focal, drug-free tissue treatment technology
utilizing nanosecond (billionth of a second) range pulsed electric
fields that directly affect the cell membrane and intracellular
structures and initiates programmed cell death in treated cells. The
unique ability of NPS to initiate cell death has the potential to
significantly benefit patients in a wide variety of medical applications
including applications in immuno-oncology and dermatology, and other
potential applications we may pursue in the future. The initiation of
programmed cell death by NPS results in a minimal inflammatory response,
which improves healing outcomes and supports the replacement of treated
tissue cells with healthy tissue cells. In cancerous lesions, NPS has
been shown in preclinical models to induce immunogenic cell death (ICD),
which exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells to
mount an adaptive immune response. Pulse Biosciences is investigating a
variety of applications for its technology that exploits the
technology’s unique biologic effect, including immuno-oncology and
dermatology. More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180430006386/en/
Source: Pulse Biosciences, Inc.
Investor Relations:
Pulse Biosciences, Inc.
Brian Dow
Sr.
Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
Solebury
Trout
Bill Kadel
646-378-2934
Bkadel@Troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran
615-414-8668
christycurran@sambrown.com
